SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

These benefits were more pronounced with long-term use, as cumulative incidence rates were not as apparent after 1 year of therapy. Additionally, SGLT-2 inhibitors showed a trend toward reducing ...

Combined strategy is effective but questions remain The view that the hyperglycaemia associated with type 2 diabetes is ...

"Empagliflozin significantly reduced CI-AKI incidence in PCI patients by enhancing renal function markers, including eGFR and ...

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

Discover how modern diabetes medications offer cardiovascular benefits, transforming diabetes care and improving outcomes worldwide.

China: Combining dapagliflozin with calorie restriction resulted in a higher rate of type 2 diabetes (T2D) remission, along ...

Akums combines two potent diabetes medicines for enhanced treatment efficacy: Our Bureau, Bengaluru Tuesday, February 4, 2025, 15:30 Hrs [IST] Akums Drugs and Pharmaceuticals, a l ...

No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.

Empagliflozin and dapagliflozin are equally effective in reducing the long-term risks of acute kidney ... “Our study suggests that SGLT2 inhibitors may provide benefit in slowing the progression ...